As per the modified supply agreement with the government, Lilly will provide an additional 150,000 doses of bebtelovimab for about $275 million. The drug has also shown effectiveness against the Omicron variant.
https://www.pharmalive.com/wp-content/uploads/2022/06/EliLilly_Reuters.jpg533800Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2022-06-29 07:31:012022-06-29 08:16:51Eli Lilly to supply additional doses of COVID antibody drug to U.S.
